Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.
Emory Women's Heart Center, Emory University School of Medicine, Atlanta, Georgia.
Am J Cardiol. 2019 Oct 1;124(7):1002-1011. doi: 10.1016/j.amjcard.2019.07.003. Epub 2019 Jul 26.
This study examines a national cohort of patients with a diagnosis of acute coronary syndrome (ACS) for the prevalence of frailty, temporal changes over time, and its association with treatments and clinical outcomes. The National Inpatient Sample database was used to identify US adults with a diagnosis of ACS between 2004 and 2014. Frailty risk was determined using a validated Hospital Frailty Risk Score based on ICD-9 codes using the cutoffs <5, 5 to 15, and >15 for low- (LRS), intermediate- (IRS), and high-risk (HRS) frailty scores, respectively. Logistic regression assessed associations of frailty with clinical outcomes, adjusted for patient co-morbidities and hospital characteristics. From 7,398,572 hospital admissions with ACS between 2004 and 2014, 86.5% of patients had LRS, 13.4% had an IRS, and 0.1% had an HRS. From 2004 to 2014, the prevalence of IRS and HRS patients increased from 8.1% to 18.2% and 0.03% to 0.18%, respectively (p <0.001 for both). The proportion of patients treated with percutaneous coronary intervention was greatest among patients with lowest frailty risk scores (LRS 42.9%, IRS 21.0%, and HRS 14.6%). Comparing HRS to LRS, there was a significant increase in bleeding complications (odds ratio [OR] 2.34, 95% confidence interval [CI] 2.03 to 2.69), vascular complications (OR 2.08, 95% CI 1.79 to 2.41), in-hospital stroke (OR 7.84, 95% CI 6.93 to 8.86), and in-hospital death (OR 2.57, 95% CI 2.18 to 3.04). Risk of frailty is common among patients with ACS, is increasing in prevalence, and is associated with differential management strategies, and outcomes during hospitalization. Increased awareness could facilitate frailty-tailored care to minimize the risk of adverse outcomes.
这项研究调查了一组患有急性冠状动脉综合征 (ACS) 的患者,以了解衰弱的流行情况、随时间的变化及其与治疗和临床结局的关系。研究使用了国家住院患者样本数据库,以确定 2004 年至 2014 年间患有 ACS 的美国成年人。使用基于 ICD-9 代码的经过验证的医院衰弱风险评分来确定衰弱风险,使用<5、5 至 15 和>15 的截定点分别表示低危 (LRS)、中危 (IRS) 和高危 (HRS) 衰弱评分。使用逻辑回归评估衰弱与临床结局的关联,并根据患者合并症和医院特征进行调整。在 2004 年至 2014 年期间,有 7398522 例 ACS 住院患者,其中 86.5%的患者患有 LRS,13.4%的患者患有 IRS,0.1%的患者患有 HRS。从 2004 年到 2014 年,IRS 和 HRS 患者的患病率从 8.1%增加到 18.2%和从 0.03%增加到 0.18%(均<0.001)。患有最低衰弱风险评分(LRS 42.9%、IRS 21.0%和 HRS 14.6%)的患者接受经皮冠状动脉介入治疗的比例最高。与 LRS 相比,HRS 患者的出血并发症(优势比 [OR] 2.34,95%置信区间 [CI] 2.03 至 2.69)、血管并发症(OR 2.08,95% CI 1.79 至 2.41)、住院期间中风(OR 7.84,95% CI 6.93 至 8.86)和住院期间死亡(OR 2.57,95% CI 2.18 至 3.04)显著增加。ACS 患者衰弱很常见,其患病率呈上升趋势,与不同的管理策略和住院期间的结局相关。提高认识可以促进量身定制的衰弱护理,以最大限度地降低不良结局的风险。